Close Menu

Tekmira

Title: Vaccine Compositions and Methods for Treatment of Mucormycosis and Other Fungal Diseases
Patent Number: 8,444,985
Filed: March 19, 2010

Officials from Tekmira Pharmaceuticals this week updated the company’s research and development efforts, stating that the company continues to expect its lead drug candidate, the cancer therapy TKM-PLK1, to move into phase II testing later this year.

Tekmira Pharmaceuticals this week announced that its contract with the US Department of Defense to develop an RNAi-based Ebola virus drug has been modified to allow for improvements made to the company’s drug formulation and manufacturing technologies.

Tekmira Pharmaceuticals this week released data from an ongoing phase I clinical trial of its RNAi-based cancer drug TKM-PLK1, showing that the drug is safe and offering hints of efficacy.

Tekmira Pharmaceuticals this week said that it has completed the main part of a phase I study of the siRNA-based cancer drug TKM-PLK1, and is slated to present the trial’s results in two weeks at the American Association for Cancer Research’s annual meeting.

Alnylam Pharmaceuticals last week announced that partner Cubist Pharmaceuticals has dropped out of its deal to develop Alnylam's investigational respiratory syncytial virus drug ALN-RSV01 following a failed phase IIb trial last year.

Tekmira Pharmaceuticals this week provided a minor update on its ongoing research and development efforts, highlighting its phase I cancer drug TKM-PLK1, which is slated to enter phase II testing later this year, and its Ebola infection treatment TKM-Ebola, which is being readied

This story has been updated to include more recent stock and market capitalization information.

Alnylam to Sell $125M in Stock

Premium

Alnylam Pharmaceuticals this week announced that it will raise $125 million through the public sale of common stock.

Though not defined by any one major breakthrough as in years past, the RNAi therapeutics field made steady progress in 2012, particularly in terms of product and technology development, according to industry insiders.

Pages

US National Institutes of Health Director Francis Collins says he will avoid male-only speaker panels.

Two patients fell ill, and one subsequently died, following a fecal microbiome transplant that harbored multi-drug-resistant bacteria, according to the New York Times.

Technology Review reports that eGenesis is testing whether organs from genetically modified pigs can be transplanted into monkeys.

In Science this week: almond reference genome, and more.